4 keys to accelerating blockbuster drug production

Longstanding biopharmaceutical companies, including contract manufacturers, often rely upon older manufacturing facilities with aging building systems. Yet, aging systems can put production volumes at risk when a piece of equipment malfunctions or fails completely. To maximize uptime,  leading biopharmaceutical manufacturers are adopting next-generation, reliability-focused maintenance methodology that enables building engineers to detect and address emerging malfunctions before a failure brings production to a halt.

Another leading practice is to use a data-driven approach to lifecycle asset management and capital planning. Using mobile technology, your real estate and facilities team can create an asset registry that includes age, warranty coverage, expected lifespan and other details, and rank potential capital investments in terms of cost, urgency and importance.

Backed by data, your team can use the objective capital plan to secure C-suite support for investments that will benefit the larger business. Combined with reliability-focused maintenance, a data-driven capital plan can help you reduce capital expenditures and, most important, improve uptime and production volume.

When you are anticipating a need to scale quickly, taking key steps can bring confidence that your laboratories and facilities are prepared to bring products to market. With key practices, tools and expertise, you can ensure the successful delivery of lifesaving treatments—and change patients’ lives for the better.

Are you ready to create value with efficient, compelling real estate and facilities that accelerate scientific innovation? Let’s chat.